Trial Profile
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Lisocabtagene-maraleucel (Primary) ; Ibrutinib; Venetoclax
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TRANSCEND-CLL-004
- Sponsors Juno Therapeutics
- 12 Dec 2023 Results of exploratory analysis (n=80) aimed to better understand potential variables associated with achieving uMRD in pts who had SD with liso-cel presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results (n=137) assessing efficacy and safety of Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 10 Dec 2023 Results presented in the Bristol-Myers Squibb Media Release.